ArticleInternational journal of cardiology2015
Prediction of development and maintenance of high albuminuria during chronic renin-angiotensin suppression by plasma proteomics.
Article in International journal of cardiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03887416 (Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes), which is not on this map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes
Who cites it
5 citing papers in PubMed, 19 citations in OpenAlex.
- Multiomics Analysis Reveals Therapeutic Targets for Chronic Kidney Disease With Sarcopenia.Journal of cachexia, sarcopenia and muscle · 2025Article
- Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals.Scientific reports · 2018Article
- Progression of Renal Insufficiency in Patients with Essential Hypertension Treated with Renin Angiotensin Aldosterone System Blockers: An Electrocardiographic Correlation.Diseases (Basel, Switzerland) · 2017Article
- Urinary exosomes reveal protein signatures in hypertensive patients with albuminuria.Oncotarget · 2017Article
- Kalirin and CHD7: novel endothelial dysfunction indicators in circulating extracellular vesicles from hypertensive patients with albuminuria.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh albuminuria is a strong predictor of development of cardiovascular events in hypertensive patients. The search for predictors identifying patients at risk of developing high albuminuria or presenting a more rapid progression in this parameter may represent an effective strategy for adequate intervention and better outcome. METHODS AND
resultsInitially we investigated 24 patients presenting with normoalbuminuria, de novo albuminuria and sustained albuminuria. Plasma proteomics disclosed an upregulation of ceruloplasmin (CP), haptoglobin (HP) and alpha 1-acid glycoprotein (ORM1) that in a second step were selected for validation using turbidimetry assay in a cohort of 105 subjects. The validation showed that HP and ORM1 proteins were increased in patients presenting with very high albuminuria and potential irreversible kidney damage. CP and HP correlated positively with albuminuria values in normoalbuminuric patients. Finally, the levels of ORM1 and CP were increased in patients who progressed in their levels of albuminuria.
conclusionsOur findings show that these proteins may potentially be useful for predicting the development of high albuminuria and to monitor renal damage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.